The Shanghai-based firm will evaluate the safety of the therapy and its efficacy in reducing urinary oxalate levels and improving renal outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback